The pharmacokinetic imperative in late-life depression

Journal of Clinical Psychopharmacology

Volumn 25, Issue 4 SUPPL. 1, 2005, Pages

  Pollock, Bruce G ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ASTEMIZOLE; CARBAMAZEPINE; CERIVASTATIN; CISAPRIDE; CITALOPRAM; DIPHENHYDRAMINE; FLUOXETINE; FLUVOXAMINE; MIDAZOLAM; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PHENYTOIN; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; STATINE DERIVATIVE; TERFENADINE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGING; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DEPRESSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG TISSUE LEVEL; FOOD DRUG INTERACTION; GERONTOPSYCHIATRY; GRAPEFRUIT JUICE; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; LAW; ONSET AGE; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOPHARMACOTHERAPY; SIDE EFFECT;

AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HUMANS; MIDDLE AGED;

EID: 23044506493     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000162809.69323.66     Document Type: Conference Paper

References (45)

1. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41:192-199.
2. Pollock BG. Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry. 1999;20(suppl 60):4-8.
3. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109:87-94.
4. Atkin PA, Veitch PC, Veitch EM, et al. The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging. 1999;14: 141-152.
5. Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 2001;18:837-851.
6. Mulsant BH, Pollock BG, Kirshner M, et al. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60:198-203.
7. Nebes RD, Pollock BG, Mulsant BH, et al. Low-level serum anticholinergicity as a source of baseline cognitive heterogeneity in geriatric depressed patients. Psychopharmacol Bull. 1997;33:715-720.
8. Kirby D, Ames D. Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry. 2001;16:484-493.
9. Furlan PM, Kalian MJ, Ten Have T, et al. Cognitive and psychomotor effects of paroxetine and sertraline on healthy elderly volunteers. Am J Geriatr Psychiatry. 2001;9:429-438.
10. Foglia JP, Pollock BG. Medication compliance in the elderly. Essential Psychopharmacol. 1997;1:243-253.
11. Bies R, Gastonguay M, Coley K, et al. Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques. Am J Geriatr Psychiatry. 2002;10:696-705.
12. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000;23: 587-590.
13. Lotrich FE, Pollock BG, Ferrell RE. Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors. Am J Pharmacogenomics. 2001;1:153-164.
14. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002;159:1702-1710.
15. De Vries MH, Van Harten J, Van Bemmel P, et al. Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm Drug Dispos. 1993;14:291-296.
16. Bergstrom RF, Lemberger L, Farid NA, et al. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry Suppl. 1988;47-50.
17. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet. 1997;1(suppl 32):22-30.
18. Hebenstreit GF, Fellerer K, Zochling R, et al. A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatr Scand Suppl. 1989;350:81-84.
19. Lundmark J. Scheel Thomsen I, Fjord-Larsen T, et al. Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand Suppl. 1989;350:76-80.
20. Foglia JP, Pollock BG, Kirshner MA, et al. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull. 1997;33:109-112.
21. Overø KF. Kinetics of citalopram in man: plasma levels in patients. Neuropsychopharmacol Biol Psychiatry. 1982;6:311-318.
22. Gutierrez M, Abramowitz W. Steady-state pharmacokinetics of citalopram in young and elderly subjects. Pharmacotherapy. 2000;20:1441-1447.
23. Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol. 1996;16:19-25.
24. Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol. 1995;35:876-884.
25. Klamerus KJ, Parker VD, Rudolph RL, et al. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy. 1996;16:915-923.
26. Timmer CJ, Paanakker JE, Van Hal HJ. Pharmacokinetics of mirtazapine from orally administered tablets: influence of gender, age and treatment regimen. Hum Psychopharmacol. 1996;11:497-509.
27. DeVane CL, Pollock BG. Pharmacokinetic considerations of antidepressant use in the elderly. J Clin Psychiatry. 1999;20(suppl 60):38-44.
28. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002.
29. Guidance for Industry: Population Pharmacokinetics. Rockville, Md: US Food and Drug Administration; 1999.
30. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol. 1992;32:185-209.
31. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115-121.
32. Pollock BG. Geriatric psychiatry: psychopharmacology: general principles. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry/VII. Baltimore, MD: Williams & Wilkins; 2000:3086-3090.
33. Murphy GM Jr, Pollock BG, Kirshner MA, et al. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology. 2001;25:737-743.
34. Pollock BG, Mulsant BH, Sweet RA, et al. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull. 1995;31:327-331.
35. Lessard E, Yessine MA, Hamelin BA, et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999;9:435-443.
36. Lessard E, Yessine MA, Hamelin BA, et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol. 2001;21:175-184.
37. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM. 2003;96:369-374.
38. Pollock BG, Perel JM, Altieri LP, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull. 1992;28:163-168.
39. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997;17:284-291.
40. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos. 2003;31:289-293.
41. Pollock BG, Wylie M, Stack JA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol. 1999;39:936-940.
42. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000;28:1176-1183.
43. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000;20: 137-140.
44. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894-1898.
45. van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;323:655-658.